Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: Correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging

Fergus Coakley, Irene Chen, Aliya Qayyum, Antonio C. Westphalen, Peter R. Carroll, Hedvig Hricak, Mei Hsiu Chen, John Kurhanewicz

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVE: To investigate the validity of prostate-specific antigen (PSA) as a tumour marker in men with clinically localized prostate cancer who have selected watchful waiting, by determining if serial PSA level measurements are correlated with findings of malignancy or benign prostatic hyperplasia (BPH) at serial endorectal magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI). PATIENTS AND METHODS: We retrospectively identified 69 men with biopsy-proven prostate cancer being managed by watchful waiting, who underwent serial endorectal MRI/MRSI and who had contemporaneous serial PSA measurements. The mean (range) follow-up was 392 (294-571) days. A panel of three experienced readers reviewed the initial and follow-up MRI/MRSI studies, and classified findings of prostate cancer as stable or progressive. Another reader assessed BPH by calculating total gland and central gland volumes on all studies. RESULTS: At the follow-up MRI/MRSI, 51, 17 and one patient had stable, progressive, or unevaluable prostate cancer, respectively. The mean PSA velocity was significantly greater in patients with radiologically progressive disease (1.42 vs 0.42 ng/mL/year, P = 0.04). A PSA velocity of >0.75 ng/mL/year identified those with radiologically progressive disease with a true-positive fraction of 0.71 and a false-positive fraction of 0.39. PSA levels were not correlated with changes in total or central gland volumes (P > 0.05). CONCLUSIONS: In men with clinically localized prostate cancer who select watchful waiting, serial PSA levels are correlated with findings of malignancy but not BPH at serial endorectal MRI/MRSI, suggesting that PSA is a useful longitudinal tumour marker in this population.

Original languageEnglish (US)
Pages (from-to)41-45
Number of pages5
JournalBJU International
Volume99
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Watchful Waiting
Prostate-Specific Antigen
Tumor Biomarkers
Prostatic Neoplasms
Magnetic Resonance Imaging
Prostatic Hyperplasia
Neoplasms

Keywords

  • Biological markers
  • MRI
  • Prostatic hyperplasia
  • Prostatic neoplasms
  • PSA

ASJC Scopus subject areas

  • Urology

Cite this

Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting : Correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. / Coakley, Fergus; Chen, Irene; Qayyum, Aliya; Westphalen, Antonio C.; Carroll, Peter R.; Hricak, Hedvig; Chen, Mei Hsiu; Kurhanewicz, John.

In: BJU International, Vol. 99, No. 1, 01.2007, p. 41-45.

Research output: Contribution to journalArticle

Coakley, Fergus ; Chen, Irene ; Qayyum, Aliya ; Westphalen, Antonio C. ; Carroll, Peter R. ; Hricak, Hedvig ; Chen, Mei Hsiu ; Kurhanewicz, John. / Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting : Correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. In: BJU International. 2007 ; Vol. 99, No. 1. pp. 41-45.
@article{271e55ccbecb44e1a57d2dc2a92dd004,
title = "Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: Correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging",
abstract = "OBJECTIVE: To investigate the validity of prostate-specific antigen (PSA) as a tumour marker in men with clinically localized prostate cancer who have selected watchful waiting, by determining if serial PSA level measurements are correlated with findings of malignancy or benign prostatic hyperplasia (BPH) at serial endorectal magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI). PATIENTS AND METHODS: We retrospectively identified 69 men with biopsy-proven prostate cancer being managed by watchful waiting, who underwent serial endorectal MRI/MRSI and who had contemporaneous serial PSA measurements. The mean (range) follow-up was 392 (294-571) days. A panel of three experienced readers reviewed the initial and follow-up MRI/MRSI studies, and classified findings of prostate cancer as stable or progressive. Another reader assessed BPH by calculating total gland and central gland volumes on all studies. RESULTS: At the follow-up MRI/MRSI, 51, 17 and one patient had stable, progressive, or unevaluable prostate cancer, respectively. The mean PSA velocity was significantly greater in patients with radiologically progressive disease (1.42 vs 0.42 ng/mL/year, P = 0.04). A PSA velocity of >0.75 ng/mL/year identified those with radiologically progressive disease with a true-positive fraction of 0.71 and a false-positive fraction of 0.39. PSA levels were not correlated with changes in total or central gland volumes (P > 0.05). CONCLUSIONS: In men with clinically localized prostate cancer who select watchful waiting, serial PSA levels are correlated with findings of malignancy but not BPH at serial endorectal MRI/MRSI, suggesting that PSA is a useful longitudinal tumour marker in this population.",
keywords = "Biological markers, MRI, Prostatic hyperplasia, Prostatic neoplasms, PSA",
author = "Fergus Coakley and Irene Chen and Aliya Qayyum and Westphalen, {Antonio C.} and Carroll, {Peter R.} and Hedvig Hricak and Chen, {Mei Hsiu} and John Kurhanewicz",
year = "2007",
month = "1",
doi = "10.1111/j.1464-410X.2006.06515.x",
language = "English (US)",
volume = "99",
pages = "41--45",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting

T2 - Correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging

AU - Coakley, Fergus

AU - Chen, Irene

AU - Qayyum, Aliya

AU - Westphalen, Antonio C.

AU - Carroll, Peter R.

AU - Hricak, Hedvig

AU - Chen, Mei Hsiu

AU - Kurhanewicz, John

PY - 2007/1

Y1 - 2007/1

N2 - OBJECTIVE: To investigate the validity of prostate-specific antigen (PSA) as a tumour marker in men with clinically localized prostate cancer who have selected watchful waiting, by determining if serial PSA level measurements are correlated with findings of malignancy or benign prostatic hyperplasia (BPH) at serial endorectal magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI). PATIENTS AND METHODS: We retrospectively identified 69 men with biopsy-proven prostate cancer being managed by watchful waiting, who underwent serial endorectal MRI/MRSI and who had contemporaneous serial PSA measurements. The mean (range) follow-up was 392 (294-571) days. A panel of three experienced readers reviewed the initial and follow-up MRI/MRSI studies, and classified findings of prostate cancer as stable or progressive. Another reader assessed BPH by calculating total gland and central gland volumes on all studies. RESULTS: At the follow-up MRI/MRSI, 51, 17 and one patient had stable, progressive, or unevaluable prostate cancer, respectively. The mean PSA velocity was significantly greater in patients with radiologically progressive disease (1.42 vs 0.42 ng/mL/year, P = 0.04). A PSA velocity of >0.75 ng/mL/year identified those with radiologically progressive disease with a true-positive fraction of 0.71 and a false-positive fraction of 0.39. PSA levels were not correlated with changes in total or central gland volumes (P > 0.05). CONCLUSIONS: In men with clinically localized prostate cancer who select watchful waiting, serial PSA levels are correlated with findings of malignancy but not BPH at serial endorectal MRI/MRSI, suggesting that PSA is a useful longitudinal tumour marker in this population.

AB - OBJECTIVE: To investigate the validity of prostate-specific antigen (PSA) as a tumour marker in men with clinically localized prostate cancer who have selected watchful waiting, by determining if serial PSA level measurements are correlated with findings of malignancy or benign prostatic hyperplasia (BPH) at serial endorectal magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI). PATIENTS AND METHODS: We retrospectively identified 69 men with biopsy-proven prostate cancer being managed by watchful waiting, who underwent serial endorectal MRI/MRSI and who had contemporaneous serial PSA measurements. The mean (range) follow-up was 392 (294-571) days. A panel of three experienced readers reviewed the initial and follow-up MRI/MRSI studies, and classified findings of prostate cancer as stable or progressive. Another reader assessed BPH by calculating total gland and central gland volumes on all studies. RESULTS: At the follow-up MRI/MRSI, 51, 17 and one patient had stable, progressive, or unevaluable prostate cancer, respectively. The mean PSA velocity was significantly greater in patients with radiologically progressive disease (1.42 vs 0.42 ng/mL/year, P = 0.04). A PSA velocity of >0.75 ng/mL/year identified those with radiologically progressive disease with a true-positive fraction of 0.71 and a false-positive fraction of 0.39. PSA levels were not correlated with changes in total or central gland volumes (P > 0.05). CONCLUSIONS: In men with clinically localized prostate cancer who select watchful waiting, serial PSA levels are correlated with findings of malignancy but not BPH at serial endorectal MRI/MRSI, suggesting that PSA is a useful longitudinal tumour marker in this population.

KW - Biological markers

KW - MRI

KW - Prostatic hyperplasia

KW - Prostatic neoplasms

KW - PSA

UR - http://www.scopus.com/inward/record.url?scp=33845512788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845512788&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2006.06515.x

DO - 10.1111/j.1464-410X.2006.06515.x

M3 - Article

C2 - 17227490

AN - SCOPUS:33845512788

VL - 99

SP - 41

EP - 45

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -